Following a career as a senior finance lawyer for global institutions including Citibank, Umaima continued practising law in the life sciences at Abcam before moving into business development at AstraZeneca, where she negotiates significant licensing and divestment transactions across multiple therapy areas.
Umaima is co-founder and Chief Business Officer of 52 North Health, a board member of the UK Pharmaceutical Licensing Group and a trustee of Cambridge Community Arts.
She is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge.
